ATE545657T1 - Tgf-beta antikörper - Google Patents
Tgf-beta antikörperInfo
- Publication number
- ATE545657T1 ATE545657T1 AT06840328T AT06840328T ATE545657T1 AT E545657 T1 ATE545657 T1 AT E545657T1 AT 06840328 T AT06840328 T AT 06840328T AT 06840328 T AT06840328 T AT 06840328T AT E545657 T1 ATE545657 T1 AT E545657T1
- Authority
- AT
- Austria
- Prior art keywords
- tgf
- beta antibodies
- antibodies
- mammal
- antigen
- Prior art date
Links
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 title 1
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 abstract 1
- 101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 abstract 1
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 abstract 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75395605P | 2005-12-23 | 2005-12-23 | |
| PCT/US2006/062397 WO2007076391A1 (en) | 2005-12-23 | 2006-12-20 | Tgf-beta binding compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE545657T1 true ATE545657T1 (de) | 2012-03-15 |
Family
ID=37898733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT06840328T ATE545657T1 (de) | 2005-12-23 | 2006-12-20 | Tgf-beta antikörper |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US7494651B2 (de) |
| EP (1) | EP1966243B1 (de) |
| JP (1) | JP2009521496A (de) |
| CN (1) | CN101346394B (de) |
| AT (1) | ATE545657T1 (de) |
| AU (1) | AU2006330542B2 (de) |
| BR (1) | BRPI0620240A2 (de) |
| CA (1) | CA2632799A1 (de) |
| ES (1) | ES2379194T3 (de) |
| WO (1) | WO2007076391A1 (de) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005097832A2 (en) * | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| CA2632799A1 (en) * | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
| US8350006B2 (en) * | 2008-10-24 | 2013-01-08 | Mead Johnson Nutrition Company | Methods for determining the bioactivity of TGF-β in a composition |
| WO2010080910A1 (en) * | 2009-01-08 | 2010-07-15 | Bio-Rad Laboratories, Inc. | Methods and compositions for improving efficiency of nucleic acids amplification reactions |
| US20120294868A1 (en) | 2009-04-24 | 2012-11-22 | Edwards James R | Anti-tgf-beta induction of bone cell function and bone growth |
| LT2714735T (lt) | 2011-06-03 | 2021-12-10 | Xoma Technology Ltd. | Tgf beta specifiniai antikūnai |
| EP2822592B1 (de) | 2012-03-08 | 2018-08-15 | Ludwig Institute for Cancer Research Limited | Spezifische tgf-1-antikörper und verfahren sowie verwendungen davon |
| WO2013134665A1 (en) | 2012-03-08 | 2013-09-12 | Selig Sealing Products, Inc. | Container sealing member with protected security component and removal tab |
| PL2976359T5 (pl) | 2013-03-20 | 2022-07-18 | Genzyme Corporation | Sposoby leczenia wrodzonej łamliwości kości |
| WO2016024628A1 (ja) * | 2014-08-14 | 2016-02-18 | 学校法人東京医科大学 | 樹状細胞の抗癌免疫賦活能の促進方法およびその用途 |
| HK1245134A1 (zh) | 2015-01-14 | 2018-08-24 | The Brigham And Women's Hospital, Inc. | 用抗lap单克隆抗体治疗癌症 |
| TWI726870B (zh) | 2015-03-04 | 2021-05-11 | 美商健臻公司 | 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體 |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| CN108136001B (zh) | 2015-04-03 | 2022-07-29 | 佐马技术有限公司 | 使用TGF-β抑制剂和PD-1抑制剂治疗癌症 |
| EP3307772B1 (de) | 2015-06-12 | 2020-09-09 | Ludwig Institute For Cancer Research Limited | Tgf-beta-3-spezifische antikörper und verfahren sowie verwendungen davon |
| AU2017268234A1 (en) | 2016-05-17 | 2018-12-13 | Genentech, Inc. | Stromal gene signatures for diagnosis and use in immunotherapy |
| GB201610044D0 (en) | 2016-06-08 | 2016-07-20 | Ucb Biopharma Sprl | Antibodies |
| EP3565839A4 (de) | 2017-01-05 | 2021-04-21 | Gensun Biopharma Inc. | Checkpoint-regulatorantagonisten |
| TW202421659A (zh) * | 2017-01-20 | 2024-06-01 | 美商健臻公司 | 骨靶向抗體 |
| CA3077664A1 (en) | 2017-11-06 | 2019-05-09 | Genentech, Inc. | Diagnostic and therapeutic methods for cancer |
| US11001635B2 (en) | 2018-06-29 | 2021-05-11 | Gensun Biopharma Inc. | Antitumor antagonists |
| CA3118027A1 (en) | 2018-11-05 | 2020-05-14 | Ludwig Institute For Cancer Research Ltd. | Humanized and variant tgf-.beta.3 specific antibodies and methods and uses thereof |
| AU2019375036A1 (en) | 2018-11-05 | 2021-06-03 | Centre Hospitalier Universitaire Vaudois | Humanized and variant TGF-beta1 specific antibodies and methods and uses thereof |
| EP3990116A1 (de) | 2019-06-28 | 2022-05-04 | Gensun Biopharma Inc. | Antitumor-antagonist bestehend aus einer mutierten tgfss1-rii-extrazellulären domäne und einem immunoglobulin-gerüst |
| CA3152371A1 (en) | 2019-08-01 | 2021-02-04 | Vaccinex, Inc. | Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor |
| CA3170142A1 (en) | 2020-02-19 | 2021-08-26 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing tfgb antagonist prodrugs useful in the treatment of cancer and methods thereof |
| CN113563473A (zh) | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2022109443A1 (en) * | 2020-11-23 | 2022-05-27 | The Regents Of The University Of Michigan | Single-chain antibody against flavivirus ns1 protein |
| WO2022115611A1 (en) | 2020-11-25 | 2022-06-02 | Catamaran Bio, Inc. | Cellular therapeutics engineered with signal modulators and methods of use thereof |
| CN112940119B (zh) * | 2021-04-26 | 2022-05-20 | 北京芳渟阳生生物科技有限公司 | 一种单克隆抗体及其与间充质干细胞外泌体的联合应用 |
| CN115707716A (zh) * | 2021-08-18 | 2023-02-21 | 丹生医药技术(上海)有限公司 | 一种TGF-β/VEGF双功能抗体融合蛋白 |
| WO2023080900A1 (en) | 2021-11-05 | 2023-05-11 | Genentech, Inc. | Methods and compositions for classifying and treating kidney cancer |
| TWI866210B (zh) | 2022-05-17 | 2024-12-11 | 大陸商蘇州創勝醫藥集團有限公司 | 雙功能蛋白質及其製劑和用途 |
| EP4599088A1 (de) | 2022-10-05 | 2025-08-13 | Genentech, Inc. | Verfahren und zusammensetzungen zur klassifizierung und behandlung von lungenkrebs |
| WO2024077095A1 (en) | 2022-10-05 | 2024-04-11 | Genentech, Inc. | Methods and compositions for classifying and treating bladder cancer |
| CN120418286A (zh) * | 2023-01-09 | 2025-08-01 | 北京拓界生物医药科技有限公司 | TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| EP1646655A2 (de) * | 2003-07-09 | 2006-04-19 | Eli Lilly And Company | Tgf-beta1 liganden |
| WO2005097832A2 (en) | 2004-03-31 | 2005-10-20 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| CA2632799A1 (en) * | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
-
2006
- 2006-12-20 CA CA002632799A patent/CA2632799A1/en not_active Abandoned
- 2006-12-20 EP EP06840328A patent/EP1966243B1/de not_active Not-in-force
- 2006-12-20 CN CN2006800485519A patent/CN101346394B/zh not_active Expired - Fee Related
- 2006-12-20 AT AT06840328T patent/ATE545657T1/de active
- 2006-12-20 AU AU2006330542A patent/AU2006330542B2/en not_active Ceased
- 2006-12-20 US US12/096,383 patent/US7494651B2/en not_active Expired - Fee Related
- 2006-12-20 WO PCT/US2006/062397 patent/WO2007076391A1/en not_active Ceased
- 2006-12-20 JP JP2008547744A patent/JP2009521496A/ja not_active Ceased
- 2006-12-20 ES ES06840328T patent/ES2379194T3/es active Active
- 2006-12-20 BR BRPI0620240-3A patent/BRPI0620240A2/pt not_active IP Right Cessation
-
2009
- 2009-02-06 US US12/366,664 patent/US20090155285A1/en not_active Abandoned
-
2010
- 2010-01-26 US US12/693,722 patent/US7927593B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20080292638A1 (en) | 2008-11-27 |
| EP1966243A1 (de) | 2008-09-10 |
| WO2007076391A1 (en) | 2007-07-05 |
| BRPI0620240A2 (pt) | 2011-11-08 |
| AU2006330542B2 (en) | 2012-05-24 |
| JP2009521496A (ja) | 2009-06-04 |
| US20100136021A1 (en) | 2010-06-03 |
| WO2007076391A9 (en) | 2008-08-28 |
| ES2379194T3 (es) | 2012-04-23 |
| CA2632799A1 (en) | 2007-07-05 |
| CN101346394B (zh) | 2012-07-25 |
| CN101346394A (zh) | 2009-01-14 |
| EP1966243B1 (de) | 2012-02-15 |
| US7494651B2 (en) | 2009-02-24 |
| AU2006330542A1 (en) | 2007-07-05 |
| US7927593B2 (en) | 2011-04-19 |
| US20090155285A1 (en) | 2009-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE545657T1 (de) | Tgf-beta antikörper | |
| NO20082905L (no) | Anti-IL-17 antistoff | |
| IL185754A0 (en) | Novel anti-plgf antibody | |
| TNSN08255A1 (en) | Anti-mn antibodies and methods of using same | |
| MXPA06014510A (es) | Composiciones y metodos para tratar trastornos inflamatorios. | |
| NO2017032I1 (no) | bezlotoksumab | |
| UA92504C2 (en) | Anti-myostatin monoclonal antibody | |
| DK2135881T3 (da) | Antistoffer, som binder til det tumor-associerede antigen TAT10772, til diagnose og behandling af tumor | |
| EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| WO2006118772A3 (en) | Fcrn antibodies and uses thereof | |
| DE602006013029D1 (de) | Anti-egfr-antikörper | |
| DK1706424T3 (da) | FC-region varianter | |
| TW200714290A (en) | Anti-M-CSF antibody compositions having reduced levels of endotoxin | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| NO20083147L (no) | Anti-OX40L-antistoffer og fremgangsmater for anvendelse av disse | |
| NO20083397L (no) | Anti-EphB4-antistoffer og fremgangsmater for anvendelse av disse | |
| ATE502052T1 (de) | Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii) | |
| WO2006074397A3 (en) | Cripto binding molecules | |
| EA201491575A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| EA200700876A1 (ru) | Агенты, специфически связывающие ангиопоэтин-2 | |
| TW200603828A (en) | Treatment of disorders | |
| WO2008085878A3 (en) | High affinity antibodies that neutralize staphylcoccus enterotoxin b | |
| IL177825A0 (en) | Natural igm antibodies and inhibitors thereof | |
| TW200738236A (en) | Certain chemical entities, compositions, and methods | |
| UA98100C2 (ru) | Гуманизированное моноклональное антитело, которое связывается с человеческим nogo и нейтрализует его |